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Summary
Background Optimal drug treatment for patients with resistant hypertension is undefi ned. We aimed to test the 
hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone 
would therefore be superior to non-diuretic add-on drugs at lowering blood pressure.
Methods In this double-blind, placebo-controlled, crossover trial, we enrolled patients aged 18–79 years with seated 
clinic systolic blood pressure 140 mm Hg or greater (or ≥135 mm Hg for patients with diabetes) and home systolic 
blood pressure (18 readings over 4 days) 130 mm Hg or greater, despite treatment for at least 3 months with maximally 
tolerated doses of three drugs, from 12 secondary and two primary care sites in the UK. Patients rotated, in a 
preassigned, randomised order, through 12 weeks of once daily treatment with each of spironolactone (25–50 mg), 
bisoprolol (5–10 mg), doxazosin modifi ed release (4–8 mg), and placebo, in addition to their baseline blood pressure 
drugs. Random assignment was done via a central computer system. Investigators and patients were masked to the 
identity of drugs, and to their sequence allocation. The dose was doubled after 6 weeks of each cycle. The hierarchical 
primary endpoints were the diff erence in averaged home systolic blood pressure between spironolactone and placebo, 
followed (if signifi cant) by the diff erence in home systolic blood pressure between spironolactone and the average of 
the other two active drugs, followed by the diff erence in home systolic blood pressure between spironolactone and 
each of the other two drugs. Analysis was by intention to treat. The trial is registered with EudraCT number 
2008-007149-30, and ClinicalTrials.gov number, NCT02369081.
Findings Between May 15, 2009, and July 8, 2014, we screened 436 patients, of whom 335 were randomly assigned. 
After 21 were excluded, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 
230 patients completed all treatment cycles. The average reduction in home systolic blood pressure by spironolactone 
was superior to placebo (–8·70 mm Hg [95% CI –9·72 to –7·69]; p<0·0001), superior to the mean of the other two active 
treatments (doxazosin and bisoprolol; –4·26 [–5·13 to –3·38]; p<0·0001), and superior when compared with the 
individual treatments; versus doxazosin (–4·03 [–5·04 to –3·02]; p<0·0001) and versus bisoprolol (–4·48 [–5·50 to –3·46]; 
p<0·0001). Spironolactone was the most eff ective blood pressure-lowering treatment, throughout the distribution of 
baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient 
were many-fold greater in the lower than higher ends of the distribution. All treatments were well tolerated. In six of 
the 285 patients who received spironolactone, serum potassium exceeded 6·0 mmol/L on one occasion.
Interpretation Spironolactone was the most eff ective add-on drug for the treatment of resistant hypertension. 
The superiority of spironolactone supports a primary role of sodium retention in this condition.
Funding The British Heart Foundation and National Institute for Health Research.
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Introduction
Resistant hypertension, defi ned as suboptimal blood 
pressure control despite treatment with at least 
three blood pressure-lowering drugs, is associated with a 
poor prognosis. This is caused by organ damage from 
prolonged exposure to suboptimal blood pressure control, 
and to the association with diabetes, chronic kidney 
disease, and obesity.1,2 The prevalence of resistant 
hypertension is estimated to be at least 10% of treated 
hypertensive patients, which would equate to a potential 
prevalence of about 100 million people globally.1,3 There 
has been a growing perception that controlling blood 
pressure in resistant hypertension is beyond the reach of 
existing drug therapies, leading to the emergence of 
device-based therapies such as renal denervation and 
baroreceptor stimulation.
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For drug treatment of resistant hypertension, 
international guidelines specifi cally refer to fourth-line 
therapy for patients, whose blood pressure is not 
controlled by treatment with three drugs, typically 
A + C + D, where “A” is an angiotensin-converting-enzyme 
(ACE) inhibitor or an angiotensin II receptor blocker 
(ARB), “C” is a calcium channel blocker (CCB), and “D” 
is a thiazide or thiazide-like diuretic.4–7 The choice of 
fourth-line drug treatment for resistant hypertension has 
been entirely empirical, refl ecting an absence of data 
from prospective randomised controlled trials comparing 
diff erent drug treatment options. The underlying 
pathophysiological basis for resistant hypertension is 
also poorly understood.
One hypothesis is that resistant hypertension is 
predominantly caused by sodium retention, due in part to 
the reduced doses of diuretics prescribed in recent years; 
if so, drugs with a diuretic action would be the most 
eff ective additional treatment.8,9 An alternative hypothesis 
is that resistant hypertension is a heterogeneous state, 
with average responses in study cohorts masking 
substantial individual patient diff erences. In the latter 
case, treatment could be stratifi ed by use of biomarkers of 
sodium/volume status, particularly plasma renin level, to 
which sodium status is inversely related.10
We selected spironolactone as the drug with diuretic 
action (through blocking the mineralocorticoid receptor) 
because of observational and limited randomised 
controlled trial data suggesting good blood pressure-
lowering effi  cacy in resistant hypertension, recently 
summarised in a meta-analysis.11 However, spironolactone 
has not been compared with alternative drugs 
recommended for resistant hypertension. It has therefore 
been unknown whether spironolactone is the most 
eff ective treatment, and if so, whether this applies to a 
subset of patients or the majority. We aimed to compare 
spironolactone with alternative fourth-line treatments 
targeting diff erent pathogenetic mechanisms: the 
α1-adrenoceptor blocker, doxazosin, acting to reduce 
peripheral resistance, and the β1-adrenoceptor blocker, 
Research in context
Evidence before this study
International guidelines have converged on a defi nition of 
resistant hypertension as blood pressure that is not controlled to 
target despite treatment with three recommended blood 
pressure-lowering drugs at maximum tolerated doses—namely, an 
angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin 
II receptor blocker (ARB; ‘‘A’’), plus a calcium channel blocker (CCB; 
‘‘C’’), plus a thiazide-like diuretic (‘‘D’’)—ie, A + C + D. We searched 
MEDLINE, Embase, and the Cochrane CENTRAL register, for 
English language publications published up to July, 2015, for 
randomised controlled trials, and open and observational studies, 
of the drug treatment of resistant hypertension. This review was 
cross-referenced to the National Institute for Health and Care 
Excellence (NICE) hypertension clinical guideline review of drug 
treatment of resistant hypertension (CG 127) from 2011 and a 
recently published meta-analysis of randomised controlled trials 
and non-randomised studies of drug treatment of resistant 
hypertension with aldosterone antagonists. The meta-analysis 
suggested that spironolactone can be an eff ective blood 
pressure-lowering treatment for patients with resistant 
hypertension, however, the NICE review concluded that the quality 
of existing evidence was low. Three randomised controlled trials, 
of 135 patients (combined), had shown spironolactone to be 
superior to the placebo in reducing seated clinic blood pressure, 
when added to existing treatment for resistant hypertension. 
But there had been no previous randomised controlled trials 
comparing spironolactone with other blood pressure-lowering 
drugs to determine if it is the most eff ective treatment for 
resistant hypertension.
Added value of this study
PATHWAY-2 is, to our knowledge, the fi rst randomised 
controlled trial to compare diff erent blood pressure-lowering 
treatments in rigorously assessed patients with resistant 
hypertension, and the fi rst comparison of mineralocorticoid 
receptor blockade with alternative recommended classes that 
block the sympathetic nervous system (α blockers and 
β blockers). The size, crossover design, and hierarchical 
primary endpoints of PATHWAY-2 enabled demonstration 
at high signifi cance (p<0·0001) that spironolactone 
25–50 mg/day is by far the most eff ective drug added to 
A + C + D, for the treatment of resistant hypertension; blood 
pressure was controlled (home systolic blood pressure 
<135 mm Hg) in 60% of patients. The role of sodium 
retention in causing resistant hypertension was strongly 
suggested by a low baseline plasma renin, despite treatment 
with three drugs which usually elevate renin, and by a 
signifi cant inverse correlation between renin and blood 
pressure reduction by spironolactone. The individual crossover 
data show that spironolactone is the most eff ective add-on 
drug, by a large margin, in the overwhelming majority of 
patients confi rmed as adherent, but resistant, to treatment 
with A + C + D.
Implications of all the available evidence
The unequivocal superiority of spironolactone, together with 
supportive effi  cacy and safety data from longer term 
observational studies, should infl uence treatment guidelines 
globally. Whether the superiority is specifi c for 
mineralocorticoid receptor blockade, refl ecting overlap between 
primary aldosteronism and resistant hypertension, will require 
comparison of spironolactone with other types of diuretic. 
Meanwhile, truly resistant hypertension can now be considered 
rare and redefi ned as blood pressure not controlled by 
A + C + D + spironolactone.
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bisoprolol, which inhibits the release of renin, and reduces 
cardiac output. Our primary aim was to determine, for the 
fi rst time, whether spironolactone is overall the most 
eff ective add-on drug treatment for resistant hypertension. 
The second aim was to determine whether plasma renin 
levels predict the most eff ective treatment for individual 
patients, and whether spironolactone would be most 
eff ective in patients with a low plasma renin as a marker 
of sodium retention. We therefore designed a randomised 
crossover trial so that each patient’s best drug and its 
predictors could be discovered.
Methods
Study design and participants
In this 12-month double-blind, placebo-controlled, 
crossover phase 4 trial, patients were enrolled from 
12 secondary care and 2 primary care sites in the UK. The 
protocol has been published.12 The trial enrolled patients 
aged 18–79 years with seated clinic systolic blood pressure 
140 mm Hg or greater (or ≥135 mm Hg for patients with 
diabetes) and home systolic blood pressure (18 readings 
over 4 days) 130 mm Hg or greater, despite treatment for 
at least 3 months with maximally tolerated doses of 
three drugs. These had to be an ACE inhibitor or an ARB; 
‘‘A’’), a CCB (‘‘C’’), and diuretic (‘‘D’’). A full list of 
eligibility and exclusion criteria is provided in the appendix 
(pp 3,4). Special emphasis was given to assessment of 
adherence to the patient’s baseline medication before 
randomisation by measurement of home systolic blood 
pressure 6 h after directly observed therapy, by returned 
tablet counts, and by measurement of serum ACE activity.
All patients gave informed written consent. The protocol 
was approved by Cambridge South Ethics Committee. 
There was no data monitoring board.
Randomisation and masking
The full trial protocol is summarised in the appendix (p 15). 
After a month’s single-blind placebo run-in, patients 
rotated through four cycles of once daily oral treatment 
with: (1) spiron olactone 25–50 mg, (2) doxazosin modifi ed 
release 4–8 mg, (3) bisoprolol 5–10 mg, and (4) placebo. The 
complete set of permutations of the sequence order for the 
four treatments in the crossover design were randomly 
ordered within blocks using computer generated pseudo 
random numbers. Study sites received the allocation 
for a particular participant by accessing a web-based 
randomisation system within the Robertson Centre for 
Biostatistics, Glasgow, Scotland, UK. The study drugs were 
masked by re-encapsulation at the Royal Free Hospital 
Pharmacy. Investigators and patients were masked to the 
identity of drugs, and to their sequence allocation.
Procedures
The treatment cycles were initiated for 6 weeks at the 
lower dose, followed by forced titration to twice this dose 
for a further 6 weeks (total of 12 weeks). Patients unable 
to tolerate a drug in a cycle were allowed to move to the 
next drug in sequence. There was no washout period 
between the four treatment cycles (three active, one 
placebo). The entire study, including placebo run-in, 
lasted 1 year. After this, patients were invited to participate 
in a further 12-week cycle of open-label amiloride 10 mg, 
titrated to 20 mg after 6 weeks.
After initial screening and enrolment, there were 
nine subsequent visits on blinded medication: one after 
the placebo run-in, the remaining eight after the 6-weekly 
periods on each of the two doses of the three active drugs 
and placebo.
The primary endpoint measurement was average home 
systolic blood pressure, recorded in the morning and the 
evening in triplicate, on 4 consecutive days before study 
visits. For analysis, a maximum of the last 18 recordings for 
each measurement period—ie, days 2–4—if all completed, 
were used. A minimum of six blood pressure recordings 
per measurement period was required for a valid 
measurement of the home systolic blood pressure average. 
The home systolic blood pressure average for the primary 
endpoint included all of the aforementioned measurements 
throughout each treatment cycle—ie, at week 6 and week 
12). For seated clinic blood pressure, the mean of the last 
two measurements was recorded as the clinic blood 
pressure. The home and clinic blood pressures were 
measured for every patient using the approved, automated 
blood pressure monitor (WatchBP Home, Microlife, 
Clearwater, FL, USA), which was allocated to the patient for 
their sole use for the duration of the trial. Patients were 
instructed by the specialist nurses in self-measurement of 
blood pressure and technique was visibly re-enforced at 
each visit, when the research nurse measured patients’ 
blood pressure using the same monitor.
Figure 1: Trial profi le
*Randomised but instructed not to take any study drug after the result of 
directly observed therapy. Participants with any follow-up were included in the 
intent-to-treat analysis and the full analysis dataset consisted of all available 
data for these participants. Per-protocol analyses included participants who 
completed all follow-up visits without major deviation from the protocol. 
ITT=intention to treat.
436 screened
88 excluded
13 did not take study drug*
335 randomised
21 no follow-up for any drug
314 with any follow-up (ITT analysis)
285 for spironolactone
282 for doxazosin
285 for bisoprolol
274 for placebo
230 completed all treatment cycles
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Plasma renin was measured at baseline (following 
run-in on background ‘‘A + C + D’’ and placebo) with 
a Diasorin Liaison automated chemiluminescent 
immunoassay for direct renin mass.13 Serum electrolytes 
were measured at every visit.
Outcomes
The primary objective was to test the hypothesis that 
spironolactone is the most eff ective add-on treatment 
for patients with resistant hypertension. The primary 
analysis used an average of home systolic blood 
pressure recorded throughout the treatment cycle. We 
prespecifi ed hierarchical primary endpoints; (1) the 
diff erence in the home systolic blood pressure between 
spironolactone and placebo, followed if signifi cant by 
(2) the diff erence in home systolic blood pressure 
between spironolactone and the average of the other 
two active drugs, (doxazosin and bisoprolol), followed if 
signifi cant by (3) the diff erence in home systolic blood 
pressure between spironolactone and each of the other 
two active drugs.
The secondary objectives included evaluation of; 
(1) clinic blood pressure responses to randomised 
treatments; (2) blood pressure control rates—ie, home 
systolic blood pressure less than 135 mm Hg; (3) whether 
plasma renin concentrations and other baseline charac-
teristics could help personalise treatment by predicting 
the best drug treatment; and (4) adverse event rates 
during each treatment cycle.
To test the hypothesis that plasma renin (measured on 
a background of three drugs—ie, A + C + D), will predict 
the most eff ective fourth-line drug, we examined the 
relationship between plasma renin and the reduction of 
home systolic blood pressure with each drug, adjusted 
for the placebo response. We also identifi ed the best 
treatment for each patient—ie, the one on which they 
achieved the lowest blood pressure, and estimated for 
each drug the relationship between baseline renin and 
the likelihood that it would provide the best response. 
Adverse events were recorded at each visit.
Statistical analysis
The sample size was estimated to be 294 patients, based 
on detecting a diff erence of 3 mm Hg (SD 12) in home 
systolic blood pressure between each of the experimental 
drugs and the placebo treatment, with 90% power using 
a single sample t test at the 0·003 signifi cance level (this 
was chosen in order that the 0·01 level could be adjusted 
for three planned comparisons). However, the 
hierarchical analysis subsequently adopted negated the 
need to adjust p values.
We tested hypotheses with the mixed eff ect models to 
analyse continuous variables, with unstructured 
covariances for repeated measures within a patient. We 
included prespecifi ed baseline covariates (sex, age, 
height, weight, smoking history, and the baseline value 
of the outcome being analysed) in the models. Least 
Mean (SD) or N (%)
Age (years) 61·4 (9·6)
Sex
Male 230 (69%)
Female 105 (31%)
Weight (kg) 93·5 (18·1)
Smoker 26 (7·8%)
Home
Systolic blood pressure (mm Hg) 147·6 (13·2)
Diastolic blood pressure (mm Hg) 84·2 (10·9)
Heart rate (beats per min) 73·3 (9·9)
Clinic
Systolic blood pressure (mm Hg) 157·0 (14·3)
Diastolic blood pressure (mm Hg) 90·0 (1·5)
Heart rate (beats per min) 77·2 (12·2)
24 h urine (mmol/24 h)
Sodium 137·1 (71·8)
Potassium 70·5 (29·5)
Blood electrolytes (mmol/L)
Sodium 139·6 (3·0)
Potassium 4·1 (0·5)
eGFR (mL/min) 91·1 (26·8)
Diabetic 46 (14%)
eGFR=estimated glomerular fi ltration rate. 
Table 1: Baseline characteristics of the patients randomised into the 
PATHWAY-2 study (n=335)
Figure 2: Home systolic and diastolic blood pressures comparing spironolactone with each of the 
other cycles
The top and bottom of each column represents the unadjusted home systolic and diastolic blood pressures, 
respectively, averaged across the mid-cycle (low-dose) and end-of-cycle (high-dose) visits (6 weeks and 12 weeks) 
in which patients received the drug. Error bars represent 95% CI. Comparisons are as described under methods for 
the primary endpoint.
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squares means for each treatment estimated from these 
models are presented. Blood pressure control and 
response rates were analysed with logistic regression 
models, which also included the baseline covariates. 
Comparisons of adverse event rates between treatments 
were done with χ² tests and Fisher’s exact p values are 
given. The probability that a drug would provide the best 
response as a function of baseline renin, was estimated 
from multinomial logistic regression.
Intention-to-treat analyses excluded only those 
participants with no primary outcome data at any follow-
up visit (21 patients). Other participants with missing 
data were included, and we assumed that data was 
missing at random (ie, its absence was unrelated to the 
unobserved value).
Analyses were done with SAS (Cary, USA) version 9.3.
The trial is registered with EudraCT number 2008-
007149-30, and ClinicalTrials.gov number, NCT02369081.
Role of the funding source
The funders had no role in the data collection, data 
analysis, or data interpretation, or the writing of the 
report. The investigators and all authors had sole 
discretion in the data analysis and interpretation, writing 
of the report, and the decision to submit for publication. 
The corresponding author had full access to all of the 
data and the fi nal responsibility to submit for publication.
Results
Between May 15, 2009, and July 8, 2014, we screened 
436 patients and randomised 335, of which 21 had no 
follow-up for any drug and were excluded from the 
intention-to-treat analysis, which comprised 314 patients 
who had any follow-up data. 285 patients received 
spironolactone, 282 doxazosin, 285 bisoprolol, and 
274 placebo; 230 patients completed all treatment cycles 
(fi gure 1; appendix p 15). Last patient visit was on 
June 5, 2015. Table 1 shows the baseline of characteristics 
of the randomised patients.
The average reduction in home systolic blood pressure 
throughout the treatment cycle with spironolactone was 
superior to each of: placebo (–8·70 mm Hg [95% CI 
–9·72 to –7·69]; p<0·0001); the mean of the other two active 
treatments (doxazosin and bisoprolol, –4·26 [–5·13 to 3·38]; 
p<0·0001); and each of the other individual treatments; 
doxazosin (–4·03 [–5·04 to 3·02]; p<0·0001) and bisoprolol 
(–4·48 [–5·50 to –3·46]; p<0·0001; fi gure 2; tables 2–4).
The diff erences in favour of spironolactone were 
greater when restricted to home systolic blood pressure 
values measured on the higher doses at the end of each 
treatment cycle (table 3). Spironolactone showed the 
largest diff erence between high and low doses (table 4); 
this was true irrespective of which treatment was 
assigned in the previous cycle. In further, prespecifi ed 
sensitivity analyses, similar diff erences in favour of 
spironolactone were seen in 230 patients who received all 
four study drugs and 216 patients on three ‘‘A + C + D’’ 
background medications (appendix pp 5–8). The steep 
dose response for spironolactone, and superiority over 
other treatments, were seen also in a parallel group 
analysis of the fi rst treatment cycle (appendix p 17).
The results for seated clinic systolic blood pressure 
largely mirror those seen with home systolic blood 
pressure except that there was a large placebo eff ect on 
clinic blood pressure that was not seen with home 
blood pressure measurement (appendix p 9). Full 
details of all blood pressure data (home and clinic), 
including diastolic pressures and heart rate are shown 
in appendix (p 10).
Overall 219 (68·9% [95% CI 63·6–73·8]) of 314 patients 
achieved target home systolic blood pressure of less than 
135 mm Hg. The comparison of control rates is shown in 
the appendix (p 11). 58% of patients had their blood 
pressure controlled with spironolactone, which was 
superior to rates for other treatments. Most patients who 
were controlled by doxazosin or bisoprolol had a still 
greater fall in blood pressure on spironolactone, which 
was consequently the most eff ective treatment in almost 
Blood pressure (mm Hg) Change from baseline (mm Hg)
Mean
Spironolactone 134·9 (134·0 to 135·9) –12·8 (–13·8 to –11·8)
Doxazosin 139·0 (138·0 to 140·0) –8·7 (–9·7 to –7·7)
Bisoprolol 139·4 (138·4 to 140·4) –8·3 (–9·3 to –7·3)
Placebo 143·6 (142·6 to 144·6) –4·1 (–5·1 to –3·1)
Mean diff erences
Spironolactone vs placebo 8·70 (–9·72 to –7·69) p<0·0001
Spironolactone vs mean bisoprolol and 
doxazosin
–4·26 (–5·13 to –3·38) p<0·0001
Spironolactone vs doxazosin –4·03 (–5·04 to –3·02) p<0·0001
Spironolactone vs bisoprolol –4·48 (–5·50 to –3·46) p<0·0001
Data are mean (95% CI). Home systolic blood pressure throughout the treatment cycle for each drug (includes data 
from mid-cycle at week 6 and the fi nal visit at week 12). Least squares means from mixed eff ects models adjusted for 
baseline covariates. Hierarchical primary endpoints each tested only if the preceding tests were signifi cant.
Table 2: Home systolic blood pressure averaged across both visits for each cycle
Blood pressure (mm Hg) Change from baseline (mm Hg)
Mean
Spironolactone 133·5 (132·3 to 134·8) –14·4 (–15·6 to –13·1)
Doxazosin 138·8 (137·6 to 140·1) –9·1 (–10·3 to –7·8)
Bisoprolol 139·5 (138·2 to 140·8) –8·4 (–9·7 to –7·1)
Placebo 143·7 (142·5 to 145·0) –4·2 (–5·4 to –2·9)
Mean diff erences
Spironolactone vs placebo –10·2 (–11·7 to –8·74) p<0·0001
Spironolactone vs mean bisoprolol and 
doxazosin
–5·64 (–6·91 to –4·36) p<0·0001
Spironactone vs doxazosin –5·30 (–6·77 to –3·83) p<0·0001
Spironolactone vs bisoprolol –5·98 (–7·45 to –4·51) p<0·0001
Data are mean (95% CI). Sensitivity analysis using only the mean home systolic blood pressure at the fi nal visit of each 
cycle (week 12).
 Table 3: Home systolic blood pressure at fi nal visit of each cycle
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60% of patients. This was at least three times the 
proportion in whom doxazosin or bisoprolol were the 
most eff ective.
The proportion of patients in whom spironolactone 
was their best drug for blood pressure lowering was 
most evident on the planned analyses of prediction by 
plasma renin of blood pressure response to each drug 
and the likelihood that diff erent drugs would be best at 
diff erent points in the plasma renin distribution. 
Figure 3 shows the relation between plasma renin 
(measured at baseline whilst patients were receiving 
their usual medication—ie, A + C + D) and the blood 
pressure-lowering response to each active treatment 
corrected for the placebo eff ect. There was a clear inverse 
relation between the home systolic blood pressure fall 
with spironolactone and plasma renin, not seen with 
bisoprolol or doxazosin. Moreover, the blood pressure 
response to spironolactone was superior to bisoprolol 
and doxazosin across most of the plasma renin 
distribution (fi gure 3). Only in a small minority of 
patients, with very high plasma renin levels, did the 
mean home systolic blood pressure response to 
doxazosin or bisoprolol overlap that to spironolactone. 
Analysis of each patient’s best drug clearly showed that, 
although spironolactone was the best blood pressure-
lowering treatment throughout almost the entire renin 
distribution, the likelihood of being superior, and the 
magnitude of this superiority, was several-fold higher for 
spironolactone than the other drugs at the lower end of 
the distribution (fi gure 3; appendix pp 18,19).
All active treatments were well tolerated with similar 
low rates of adverse events and withdrawals due to adverse 
events (table 5; appendix p 12 shows the numbers and 
rates of the commonest adverse events, and appendix p 13 
shows all serious adverse events). Notably, discontinuations 
due to renal impair ment, hyperkalaemia, and 
gynaecomastia were not increased with spironolactone 
relative to other treatments and placebo. Serum sodium 
was reduced with spironolactone (–1·91 mmol/L, 
–1·35%), but not the other treatments, whereas some 
increase in potassium levels was observed with both 
bisoprolol and spironolactone (appendix p 14). Serum 
creatinine levels increased and estimated glomerular 
fi ltration rate (eGFR) decreased (appendix p 14). Stacking 
of the distribution of serum sodium, potassium, and 
eGFR at the end of the treatment cycle for each drug 
shows that all drugs lowering blood pressure in this 
population cause some fall in eGFR, and that the 
frequency of abnormal numbers for each parameter is low 
(fi gure 4). None of these was clinically serious or led to 
withdrawals from the trial. Only six (2%) of 285 patients 
exposed to spironolactone developed a serum potassium 
on a single occasion greater than 6·0 mmol/L, with a 
maximum of 6·5 mmol/L.
Discussion
PATHWAY-2 is the fi rst randomised controlled trial to 
compare spironolactone with other blood pressure-
lowering drug treatments in a well-characterised 
population of patients with resistant hypertension. The 
study shows that spironolactone was by far the most 
eff ective blood pressure-lowering treatment for patients 
with resistant hypertension. This was true in terms of the 
magnitude of the blood pressure response, the proportion 
of patients achieving a stringent measure of blood 
pressure control (home systolic blood pressure 
Blood pressure (mm Hg) p value
Spironolactone –3·86 (–5·28 to –2·45) <0·0001
Doxazosin –0·88 (–2·32 to 0·56) 0·23
Bisoprolol –1·49 (–2·94 to –0·04) 0·04
Placebo –0·68 (–2·10 to 0·75) 0·35
Diff erence in mean home systolic blood pressure after treatment with the lower 
(week 6) and higher doses (week 12) of each treatment.
Table 4: Home systolic blood pressure dose response (higher vs lower dose)
Figure 3: Blood pressure response versus renin
Regression (90% CI) of placebo corrected change in home systolic blood pressure versus renin for spironolactone 
(r²=0·037, p=0·003), doxazosin (r²=0·007, p=0·183), and bisoprolol (r²=0·0004, p=0·750). Blood pressures were 
averaged across the mid-cycle and end-of-cycle visits (6 and 12 weeks) for every treatment cycle. The distribution 
curve is fi tted to the baseline renins observed in the study. The vertical dashed line shows that the blood pressure 
fall on bisoprolol numerically exceeds that on spironolactone only in the top 3% of the renin distribution. A more 
detailed histogram for plasma renin is shown in the appendix (p 20).
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Spironolactone Doxazosin Bisoprolol Placebo p value*
Serious adverse events 7 (2%) 5 (2%) 8 (3%) 5 (2%) 0·82
Any adverse event 58 (19%) 67 (23%) 68 (23%) 42 (15%) 0·036
Withdrawals for adverse events 4 (1%) 9 (3%) 4 (1%) 3 (1%) 0·28
Data are n (%). *p values for Fisher’s exact test. The most common adverse events in at least 5% of patients on any 
treatment are shown in appendix p 12.
 Table 5: Adverse events and withdrawals
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<135 mm Hg), and the proportion in whom it was more 
eff ective than either of the non-diuretic alternative drugs. 
These fi ndings suggest that the predominant underlying 
pathophysiological cause of resistant hypertension is 
sodium retention, despite existing baseline diuretic 
therapy. This conclusion is supported by our fi nding 
that the response to spironolactone had a clear inverse 
relation with plasma renin, was especially eff ective at 
lower plasma renin levels, and yet the most eff ective drug 
throughout the range of plasma renin.
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Figure 4: Distribution of potassium (A), sodium (B), and estimated glomerular fi ltration rate (eGFR; C) on each drug
Values on the x axis are the measurement at the end of each 12-week cycle, and the y axis represents the number of patients with values in each bin on the x axis.
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Bisoprolol and doxazosin were more eff ective than 
placebo at reducing blood pressure as so-called add-on 
therapy for resistant hypertension, but signifi cantly less 
eff ective than spironolactone. Thus, this study has for the 
fi rst time, established a clear hierarchy for drug treatment 
of resistant hypertension in which spironolactone is the 
most eff ective add-on therapy (ie, fourth-line drug in 
addition to A + C + D) for most patients. Bisoprolol or 
doxazosin are less eff ective alternatives for those 
intolerant of spironolactone.
PATHWAY-2 is the fi rst study to use home blood 
pressure averages rather than clinic blood pressure to 
assess the primary outcome of blood pressure response 
in patients with resistant hypertension. This is important 
because home blood pressure measurement reduces the 
placebo eff ect, as was evident in our study, and eliminated 
patients whose blood pressure could have been spuriously 
elevated at baseline due to so-called white coat 
hypertension. Indeed, we noted a large placebo eff ect 
on clinic systolic blood pressure readings, exceeding 
10 mm Hg (table 3), which points to important 
confounding in interpreting data from previous studies 
that have relied on clinic blood pressure readings alone 
to assess the effi  cacy of drug and non-drug-based 
interventions in these patients. The magnitude of home 
systolic blood pressure reduction with spironolactone 
versus placebo (–8·7 mm Hg) in the present study is 
consistent with data from two smaller randomised 
controlled trials versus placebo that have used ambulatory 
blood pressure monitoring (secondary analysis) to 
measure changes in mean daytime pressures 
(–7·31 mm Hg).11,14,15 The reduction in seated clinic systolic 
blood pressure with spironolactone (–20·7 mm Hg) was 
also similar to the reduction in clinic blood pressure from 
meta-analysis of previous small randomised contolled 
trials versus placebo (–24·3 mm Hg) and single arm 
studies with no comparator (–22·7 mm Hg).11
Spironolactone substantially increased the likelihood 
of achieving blood pressure control relative to bisoprolol 
or doxasosin, with almost 60% achieving blood pressure 
control within 3 months of starting treatment. This 
challenges the concept that resistant hypertension cannot 
be treated adequately with existing drug therapies, a 
concept that might have contributed to the growth of 
non-drug-based therapies such as renal denervation. 
Indeed, only 15 of 285 patients assessed on spironolactone 
failed to achieve a home systolic blood pressure lower 
than 150 mm Hg (equivalent to a clinic systolic blood 
pressure of roughly 160 mm Hg), the usual eligibility 
criterion for denervation. Furthermore, it is clear from 
our data that spironolactone, unlike bisoprolol or 
doxazosin, exhibited a signifi cant dose response with 
regard to the magnitude of blood pressure lowering. A 
previous crossover comparison of spironolactone with 
even higher doses (ie, 50–100 mg) in patients without 
resistant hypertension, also showed a dose response,16 
suggesting that the highest dose of spironolactone used 
in our study (ie, 50 mg), might not be at the top of the 
dose range, and hence the potential for even better 
control rates with higher doses.
The superior response to spironolactone, compared 
with the other drugs, particularly in patients at the lower 
end of the distribution of plasma renin, supports the 
hypothesis that the predominant cause of resistant 
hypertension is sodium retention. The fact that 
spironolactone was the most eff ective drug across a wide 
range of baseline plasma renin values does not negate 
the hypothesis, because one would expect plasma renin 
levels to be elevated in patients receiving treatment with 
A + C + D, all of which usually increase plasma renin 
levels. Indeed, because plasma renin is substantially 
aff ected by background antihypertensive treatment, the 
interpretation and recognition of so-called low renin 
status has been uncertain in such populations. The 
median renin in PATHWAY-2, 34 mU/L, is roughly 
three times higher than that in the PATHWAY-1 study, of 
600 patients with untreated hypertension (unpublished). 
However, 34 mU/L is a lower median than expected if the 
sole infl uence on baseline renin was drug treatment.10 It 
is probable that plasma renin in resistant hypertension is 
relatively suppressed by sodium retention, even though 
absolute values appear normal or high.
One contributor to the sodium retention could be 
under-dosing of background diuretic treatment. An 
alternative or additional possibility is that some patients 
with resistant hypertension have undetected aldosterone 
producing adenomas (APAs). Recent studies have shown 
that specifi c somatic mutations in the adrenal gland can 
result in micro-APAs, which are diffi  cult to detect by 
conventional imaging.17 Additionally, some high-renin 
patients will have an element of secondary aldosteronism, 
explaining why spironolactone retains some effi  cacy at 
the upper end of the renin distribution. Determination of 
whether spironolactone is particularly eff ective treatment 
for resistant hypertension because it antagonises the 
eff ects of aldosterone will require a head-to-head 
comparison of spironolactone with an increase in dose of 
the background diuretic.
As well as being the most eff ective treatment for 
resistant hypertension, spironolactone was well tolerated. 
The doses of spironolactone used in the present study are 
low compared with the 200–400 mg daily used in other 
clinical circumstances. The 25–50 mg daily doses in 
PATHWAY-2 are consistent with previous studies of 
resistant hypertension in which 25 mg was the most 
common daily dose.11 These studies have shown that the 
main biochemical eff ects associated with spironolactone 
treatment are a reduction in serum sodium and an 
increase in potassium. We noted a magnitude of change 
(–1·19 mmol/L in sodium and 0·45 mmol/L in potassium) 
very similar to that reported in summary data from 
previous studies.11 Despite almost 14% of our patients 
having type 2 diabetes, only six patients receiving 
spironolactone developed potassium levels in excess of 
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6·0 mmol/L, which was detected by our routine 
monitoring and had no clinical consequence. We also 
recorded reductions in eGFR with all active blood 
pressure-lowering treatments that most likely refl ect a 
reduction in renal perfusion pressure with blood pressure 
lowering. Thus, although spironolactone is both very 
eff ective and safe in resistant hypertension, it is important 
to monitor electrolytes (especially potassium) and renal 
function during the weeks after initiation of treatment, 
after dose escalation and periodically thereafter. A recent 
large longitudinal population study of the use of 
spironolactone showed no evidence of any increased 
incidence of admission to hospital or outpatient 
hyperkalaemia.18 Another recognised adverse eff ect of 
spironolactone treatment relates to its anti-androgen 
eff ects and the development of gynaecomastia, which has 
been reported to occur in roughly 6% of men.11,19 We did 
not observe any cases in the present study, but this most 
likely refl ects the relatively short duration of our study 
(3 months exposure).
The PATHWAY-2 study has some limitations. 3 months 
treatment exposure is relatively short. Nevertheless, 
observational studies of longer spironolactone treatment 
duration for resistant hypertension suggest that the 
magnitude of the initial blood pressure response is 
durable and that among adverse events, only 
gynaecomastia is exposure dependent.11,19 The results of 
open-label treatment with amiloride (10–20 mg daily) 
during the run-out phase of our study will be reported 
later and will help to determine whether amiloride is an 
eff ective alternative to spironolactone. Our study 
excluded patients with an eGFR less than 45 mL/min, as 
have previous studies, thus there are no data on the 
safety profi le of spironolactone in patients with resistant 
hypertension and an eGFR less than 45 mL/min. Our 
study included predominantly white Caucasian patients, 
thus it is unclear whether the results are applicable to 
other ethnic groups, however, spironolactone has been 
shown to be just as eff ective in a small observational 
study that included black American patients.20 The 
absence of washout periods, inherent in a study design 
already 1 year in length, might be considered a concern. 
However, we were confi dent from our previous crossover 
studies16 that carry-over would not be a problem, and are 
supported by the sensitivity analyses, including the 
absence of change in blood pressure during the placebo 
cycle, and similarity of the primary outcome result to the 
retrospective parallel group analysis of cycle 1 alone. At 
worst, we could have under estimated the superiority of 
spironolactone. Finally, the study does not include data 
for morbidity and mortality outcomes but blood pressure 
lowering is a powerful surrogate for clinical benefi t, 
especially in this high-risk group of patients.
Our study also has a number of strengths. The 
patients in this study were particularly well 
characterised as resistant hypertension, with the use of 
home blood pressure monitoring to exclude so-called 
white coat hypertension, standardisation of background 
medication (A + C + D), directly observed therapy to 
exclude patients non-compliant with background 
medication, measurement of serum ACE to allow 
retrospective confi rmation of the expected diff erence 
in distribution between patients receiving ACE 
inhibitor or ARB as one of their background drugs, and 
oversight by national specialist hypertension centres to 
exclude secondary hypertension. In the late stages of 
the study, we incorporated a new assay for monitoring 
all commonly administered antihypertensive drugs in 
patients’ urine,21 and will report results from this 
substudy that strongly support a high adherence rate 
among our patients. Another strength was the design 
of the study, which incorporated a random cross over 
design, allowing each patient’s best drug to be 
determined, and predictive testing of this to be 
assessed. Mechanistic haemodynamic substudies, 
which could add to the predictive value of renin and 
help us to understand the pathophysiology of resistant 
hypertension, were included at most sites and will 
be reported separately.12 Finally, this was the fi rst 
randomised controlled trial directly comparing 
diff erent active drug treatments in resistant hyper-
tension and it produced an unequivocal result.
The results of PATHWAY-2 have broad international 
relevance because of convergent guideline recom-
mendations, which recommend A + C + D as the preferred 
three-drug combination at step 3.22 Our fi nding, that 
spironolactone was clearly the most eff ective treatment 
for resistant hypertension, should infl uence future 
treatment guidelines and clinical practice globally. The 
fi nding could indeed stimulate an early redefi nition of 
resistant hypertension to include a trial of spironolactone 
before the label is applied. A longer-term question is 
whether the antecedent to resistant hypertension is under 
treatment or wrong treatment, with the resistance to 
conventional drugs marking a subpopulation in whom 
spironolactone should be used at an earlier stage.
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